Anemia, Iron Deficiency
Conditions
Brief summary
We have been well guided in the "Good use of blood" during major surgery for many years, reaching a percentage of 4% of patients transfused after elective prosthetic operations. Valid patient blood management must provide for the possibility of limiting/zeroing the transfusion risk dependent on preoperative anemia, and the national guideline on PBM (Patient blood management) also underlines this Hypothesis and relevance
Detailed description
We want to analyse patients from a diagnostic point of view (occult blood, diverticulitis, gastrorrhagia) and from the point of view of laboratory parameters (blood count, serum iron, transferrinemia, ferritinemia, transferrin saturation) in ordr to be able to suggest the best approach in preparation to the intervention. We want to evaluate the effectiveness of this approach, considering the proposed treatments (ferric carboxymaltose, chelated iron, folic acid, sideremil vita) and the transfusion result (or not) obtained
Interventions
DIETARY_SUPPLEMENTsideremil vita cp
assunzione per 30 giorni dell'integratore
Sponsors
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Candidates for prosthetic surgery * Patients of both sexes over 40 years of age * Hemoglobin values \<12 g% for females and 13 g% for males and/or % transferrin saturation \< 10% * Willingness and ability to provide informed consent.
Exclusion criteria
* Patients with Mediterranean anemia * Patients with coagulation disorders * Patients who do not sign the consent form * Pregnant or breastfeeding women (self-declaration) * Minor aged
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduction in transfusion patients | 7 days post-surgery | Evaluate the reduction of transfusions in anemic patients treated with SideremilVita, with comparison between a treatment for 30 days before the intervention (group B ), compared to patients assuming SideremilVita at 15 days before surgery (group A) |
Countries
Italy
Outcome results
None listed